<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055586</url>
  </required_header>
  <id_info>
    <org_study_id>CASE3Y12</org_study_id>
    <secondary_id>NCI-2013-01177</secondary_id>
    <nct_id>NCT02055586</nct_id>
  </id_info>
  <brief_title>FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents</brief_title>
  <official_title>A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission&#xD;
      tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with&#xD;
      metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic&#xD;
      procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      The primary objective of this pilot imaging study is to determine the feasibility of&#xD;
      FLTPET/MR imaging for early prediction of treatment response in patients undergoing&#xD;
      antiangiogenic cancer treatment. The study will assess PET/MRI test-retest reproducibility&#xD;
      and compare baseline PET/MRI with PET/MRI after initiation (within 2-4 weeks) of&#xD;
      antiangiogenic therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  To compare early changes in PET biomarker (FLT) tumor uptake with treatment response&#xD;
           assessed at completion of therapy (prediction of treatment response).&#xD;
&#xD;
        -  To compare changes in MRI signal intensities (multi-parametric MRI) with treatment&#xD;
           response assessed at completion of therapy.&#xD;
&#xD;
        -  To compare results from multi-parametric MR imaging with FLT tumor uptake.&#xD;
&#xD;
        -  To assess combinations of quantitative PET and MRI metrics.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2013</start_date>
  <completion_date type="Actual">December 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance analysis of standardized uptake values (SUVs) between the 2 baseline scans</measure>
    <time_frame>Baseline</time_frame>
    <description>A sample size of 20 produces a two-sided 95% confidence interval [0.553, 0.918] for the Pearson correlation coefficient when the sample correlation is 0.80. Additional analysis for concordance will include Bland-Altman plots and intraclass correlation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparative Analysis of PET/MRI Images</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Describe changes in images at baseline PET/MRI scan compared to PET/MRI image taken after initiation of anti-angiogenic therapy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Diagnostic (FLT-PET/MRI)</arm_group_label>
    <description>Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorine F 18 fluorothymidine</intervention_name>
    <description>Undergo FLT-PET/MRI</description>
    <arm_group_label>Diagnostic (FLT-PET/MRI)</arm_group_label>
    <other_name>18F-FLT</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>fluorothymidine F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo FLT-PET/MRI</description>
    <arm_group_label>Diagnostic (FLT-PET/MRI)</arm_group_label>
    <other_name>PET/MR</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>Undergo FLT-PET/MRI</description>
    <arm_group_label>Diagnostic (FLT-PET/MRI)</arm_group_label>
    <other_name>MRI</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic solid tumors scheduled to undergo treatment with novel cancer&#xD;
        therapeutic agents as SOC treatment at a cancer center hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic solid tumors scheduled to undergo treatment with novel cancer&#xD;
             therapeutic agents as standard of care (SOC) treatment.&#xD;
&#xD;
          -  Patients able to tolerate PET/MRI scans&#xD;
&#xD;
          -  Informed consent must be given and signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who do not meet the above mentioned inclusion criteria&#xD;
&#xD;
          -  Subjects who refuse to give and/or sign the informed consent&#xD;
&#xD;
          -  Patients who currently have a pacemaker&#xD;
&#xD;
          -  Patients who have a history of serious adverse events related to a previous MRI or&#xD;
             PET/CT&#xD;
&#xD;
          -  Patients who are unable to undergo MRI scanning due to exclusion by UHCMC MRI&#xD;
             restriction policies as mentioned in the standard UHCMC MRI informed consent form&#xD;
&#xD;
          -  Patients with a known allergy against any component of the contrast enhancing agent&#xD;
&#xD;
          -  Patients who currently pregnant or breast feeding; negative serum pregnancy test&#xD;
             within 72 hours of their first FLT-PET/MRI&#xD;
&#xD;
          -  Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 4 weeks&#xD;
&#xD;
          -  Renal insufficiency: elevated creatinine and/or glomerular filtration rate (GFR) &lt; 40&#xD;
             ml/min/1.73^2 (exclusion criterion only for contrast enhanced MRI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Avril</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

